Stockscreener 앱 받기
93.01
10.44%
-10.84
전일 마감가:
$103.85
열려 있는:
$101.67
하루 거래량:
369.25K
Relative Volume:
0.81
시가총액:
$1.36B
수익:
$1.30M
순이익/손실:
$-140.06M
주가수익비율:
-10.28
EPS:
-9.0441
순현금흐름:
$-129.83M
1주 성능:
-4.68%
1개월 성능:
+3.96%
6개월 성능:
+27.66%
1년 성능:
+343.33%
1일 변동 폭
$91.76
$102.20
1주일 범위
$91.76
$106.40
52주 변동 폭
$20.48
$155.29
인히브릭스 Stock (INBX) Company Profile
명칭
Inhibrx Biosciences Inc
전화
(858) 795-4220
주소
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
93.01 | 1.36B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
인히브릭스 Stock (INBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 개시 | Stifel | Buy |
| 2024-07-23 | 개시 | JMP Securities | Mkt Perform |
| 2024-01-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | 개시 | SMBC Nikko | Outperform |
| 2021-09-21 | 개시 | JMP Securities | Mkt Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Evercore ISI | Outperform |
모두보기
인히브릭스 주식(INBX)의 최신 뉴스
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice - Yahoo Finance
Top Cybin (HELP) Competitors 2026 - MarketBeat
INBX Q1 2026 Earnings: Wider-than-Expected Loss Despite Modest Stock GainEarnings Growth Analysis - dars.gov.et
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors - simplywall.st
(INBX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2500 Growth Benchmark - marketscreener.com
INBX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Company Reports No Revenue - dars.gov.et
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2000 Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell Microcap Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000 Growth Benchmark - marketscreener.com
Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In? - Sahm
Enterprise value to revenue forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
Price to sales forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
INBX News | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Inhibrx Biosciences urges continued research to address unmet needs in rare cancer treatment - Traders Union
Inhibrx Biosciences, Inc. Actuals & Estimates (NASDAQ:INBX) - TradingView
INBX Forecast — Price Target — Prediction for 2027 - TradingView
Inhibrx Biosciences Inc (INBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More - RTTNews
The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart - Sahm
Inhibrx Biosciences (INBX) Gains 2.44%, Approaches Key Resistance at $99.93Order Block - dars.gov.et
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
INBX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline AdvancesEarnings Sentiment Score - dars.gov.et
(INBX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Inhibrx Biosciences (INBX) Stock Near Analyst Target After FDA Filing for Ozekibart - Sahm
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history - Bitget
Inhibrx Biosciences Inc (INBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences Inc (INBX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibrx Biosciences Inc (INBX) Institutional Confidence - TradingKey
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inhibrx Biosciences Inc (INBX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com - Investing.com Australia
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Pa - GuruFocus
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy - TipRanks
FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy - Stock Titan
FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com - Investing.com Australia
FDA accepts Inhibrx Biosciences filing for ozekibart in metastatic chondrosarcoma - Traders Union
Inhibrx Biosciences stock gains after FDA accepts drug filing - Investing.com
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients With Conventional Chondrosarcoma - Moomoo
Number of shareholders of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
(INBX) Risk Channels and Responsive Allocation - Stock Traders Daily
INBX Q1 2026 Earnings: EPS Misses Estimates as Stock Gains on Operational UpdatesRetail Earnings Report - newsline.com
Inhibrx Biosciences (INBX) director receives 15,000 stock options at $95.22 strike - Stock Titan
Inhibrx Biosciences (INBX) director receives grant of 15,000 stock options - Stock Titan
Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22 - Stock Titan
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting - TipRanks
Inhibrx Biosciences (NASDAQ: INBX) investors approve directors and BDO - Stock Titan
인히브릭스 (INBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):